Zimmer Biomet Holdings Analyst Ratings
Morgan Stanley Cuts Price Target on Zimmer Biomet Holdings to $120 From $130, Keeps Equalweight Rating
Citigroup Adjusts Price Target on Zimmer Biomet to $134 From $120
Zimmer Biomet Holdings Analyst Ratings
Citigroup Maintains Neutral on Zimmer Biomet Holdings, Lowers Price Target to $120
Goldman Sachs Adjusts Price Target on Zimmer Biomet Holdings to $118 From $129
Evercore ISI Adjusts Price Target on Zimmer Biomet Holdings to $115 From $130, Maintains In-Line Rating
Piper Downgrades Zimmer to Neutral, Cites Lack of Catalysts
Zimmer Biomet Holdings Analyst Ratings
Zimmer Biomet Holdings Analyst Ratings
Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $125
Zimmer Biomet Holdings (ZBH) Receives a Buy From Piper Sandler
Barclays Remains a Sell on Zimmer Biomet Holdings (ZBH)
Analysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Cellectis SA (CLLS) and Sanofi (OtherSNYNF)
Stifel Nicolaus Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
Zimmer Biomet Holdings (ZBH) Receives a Buy From RBC Capital
Zimmer Biomet Holdings: Strategic Growth and M&A Outlook With a Hold Rating
Analysts Offer Insights on Healthcare Companies: Centene (CNC), Zimmer Biomet Holdings (ZBH) and Madrigal Pharmaceuticals (MDGL)
Zimmer Biomet Holdings Analyst Ratings
Buy Rating on Zimmer Biomet Holdings With a Positive Growth Outlook and Strategic Focus